中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

90 records (took 0.029 seconds)

    De-Centralization Of Group Administration Authority
    61.
    发明申请
    De-Centralization Of Group Administration Authority 有权
    集体行政权力集中化

    公开(公告)号：US20090055901A1

    公开(公告)日：2009-02-26

    申请号：US11963646

    申请日：2007-12-21

    Applicant: Kartik Kumar ,  James Hartwell Holl, II ,  Anshu U. Surana ,  Ravindra Kumar

    Inventor： Kartik Kumar ,  James Hartwell Holl, II ,  Anshu U. Surana ,  Ravindra Kumar

    IPC: H04L9/32

    CPC classification number: H04L63/20 ,  G06F21/604 ,  H04L63/105

    Abstract: An embodiment of a network manager permits a resource group administrator (with resource group level permissions but without global permissions) to add a global object to his/her resource group as a managed object, without requiring the administrator to have a global permission, as discussed further below. An embodiment of the network manager permits a resource group administrator to also edit the configuration settings that are attached to his/her resource group without requiring the administrator to have a global permission.

    Abstract translation: 网络管理员的一个实施例允许资源组管理员（具有资源组级别权限，但没有全局权限）将全局对象添加到他/她的资源组作为被管理对象，而不要求管理员具有全局权限，如所讨论的 进一步在下面。 网络管理员的一个实施例允许资源组管理员还编辑附加到他/她的资源组的配置设置，而不需要管理员具有全局权限。

    Variants derived from ACTRIIB and uses therefor
    62.
    发明申请
    Variants derived from ACTRIIB and uses therefor 有权
    衍生自ACTRIIB的变体并用于此

    公开(公告)号：US20090005308A1

    公开(公告)日：2009-01-01

    申请号：US12012652

    申请日：2008-02-04

    Applicant: John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

    Inventor： John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

    IPC: A61K38/00 ,  C07K14/00 ,  A61P31/00 ,  C07K16/18

    CPC classification number: C07K14/71 ,  A61K38/00 ,  C07K14/705 ,  C07K14/72 ,  C07K16/18 ,  C07K2319/30 ,  C07K2319/70

    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

    Abstract translation: 在某些方面，本发明提供用于调节（促进或抑制）组织如骨，软骨，肌肉，脂肪和/或神经元组织的生长的组合物和方法。 本发明还提供筛选调节ActRIIB蛋白和/或ActRIIB配体的活性的化合物的方法。 本文提供的组合物和方法可用于治疗与ActRIIB蛋白和/或ActRIIB配体的异常活性相关的疾病。

    Firmware ROM Patch Method
    63.
    发明申请
    Firmware ROM Patch Method 有权
    固件ROM补丁方法

    公开(公告)号：US20080184072A1

    公开(公告)日：2008-07-31

    申请号：US11669776

    申请日：2007-01-31

    Applicant: Andrew J. Odlivak ,  Ravindra Kumar ,  Warren R. Stearns ,  John Glen Rockford

    Inventor： Andrew J. Odlivak ,  Ravindra Kumar ,  Warren R. Stearns ,  John Glen Rockford

    IPC: G06F11/07

    CPC classification number: G06F11/3644 ,  G06F11/3628 ,  G06F11/3648

    Abstract: A system in which firmware residing in ROM may be upgraded without re-spinning silicon. A one-bit flag may be assigned for each patchable function representing a firmware upgrade. The first statement of each function may check its associated flag and determine if patch-code should be executed in place of the current function residing in ROM. If the flag is not set, the code may continue executing normally. If the flag is set, a function identifier may be placed into a global memory location, and an assembly language “jump” instruction may be executed, redirecting program control to a specified location in a volatile Scratch Read Only Memory (SROM) where the corresponding patched code may be stored. If more than one function is patched, the global identifier may be used to determine which patched function to execute. Using an assembly language “jump” instruction to redirect control results in the patched function's returning normally to its calling function once it has completed executing.

    Abstract translation: 驻留在ROM中的固件可以升级而不需要重新硅芯片的系统。 可以为表示固件升级的每个可修补功能分配一位标志。 每个功能的第一个语句可以检查其关联的标志，并确定是否应该执行补丁代码来代替驻留在ROM中的当前功能。 如果未设置标志，则代码可能会继续正常执行。 如果标志被设置，则可以将功能标识符放置到全局存储器位置中，并且可以执行汇编语言“跳转”指令，将程序控制重定向到易失性的只读存储器（SROM）中的指定位置，其中相应的 可以存储修补代码。 如果修复了多个功能，则可以使用全局标识符来确定要执行的修补功能。 使用汇编语言“跳转”指令重定向控制结果，修补后的函数在完成执行后正常返回到调用函数。

    Lefty, Lefty derivatives and uses thereof
    65.
    发明申请
    Lefty, Lefty derivatives and uses thereof 有权
    Lefty，Lefty衍生物及其用途

    公开(公告)号：US20070042958A1

    公开(公告)日：2007-02-22

    申请号：US11479181

    申请日：2006-06-30

    Applicant: John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

    Inventor： John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

    IPC: A61K38/17 ,  C07K14/705 ,  C07H21/04 ,  C12P21/06

    CPC classification number: C07K14/47 ,  A61K38/00 ,  C07K14/495

    Abstract: The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, Lefty polypeptides are useful in the treatment of a variety of disorders, including, for example, neuronal diseases, muscle and bone conditions, and metabolic disorders.

    Abstract translation: 本公开涉及Lefty衍生物和Lef多肽作为某些配体如Nodal，GDF-8（Myostatin）和GDF-11功能的拮抗剂的用途。 这些衍生物可以与其它功能异源蛋白如IgG，特别是IgG的Fc部分融合。 根据该公开内容，Lefty多肽可用于治疗各种疾病，包括例如神经元疾病，肌肉和骨骼状况以及代谢紊乱。

Patent Agency Ranking